BriaCell Therapeutics Corp. Quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD from Q2 2021 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
BriaCell Therapeutics Corp. quarterly Accounts Receivable, after Allowance for Credit Loss, Current history and growth rate from Q2 2021 to Q1 2024.
  • BriaCell Therapeutics Corp. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending April 30, 2024 was $15.2K, a 2.26% increase year-over-year.
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q1 2024 $15.2K +$337 +2.26% Apr 30, 2024 10-Q 2024-06-14
Q4 2023 $30.1K +$21.2K +238% Jan 31, 2024 10-Q 2024-03-18
Q3 2023 $21.4K -$8.29K -27.9% Oct 31, 2023 10-Q 2023-12-14
Q2 2023 $18.9K -$5.23K -21.7% Jul 31, 2023 10-Q 2024-06-14
Q1 2023 $14.9K Apr 30, 2023 10-Q 2023-06-14
Q4 2022 $8.93K Jan 31, 2023 10-Q 2023-03-16
Q3 2022 $29.7K Oct 31, 2022 10-Q 2022-12-14
Q2 2022 $24.1K +$11.5K +91.7% Jul 31, 2022 10-K 2023-10-25
Q2 2021 $12.6K Jul 31, 2021 10-K 2022-10-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.